- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04396249
tVNS for Cognitive Impairments in Community-Dwelling Elderly
Transcutaneous Vagus Nerve Stimulation for Cognitive Impairments in Community-Dwelling Elderly
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Transcutaneous vagal nerve stimulation (tVNS) is a non-invasive neurostimulation technology.Recent studies have found that tVNS may involve in the regulation of cognition and improve the memory of the elderly.However, due to the limited number of studies, the effect of tVNS on improving cognitive function and stimulation parameters are currently unclear.
To investigate the effects of tVNS on improving cognition in community-dwelling elderly people, our study will recruit 120 subjects. Participants will undergo baseline cognitive assessment, EEG and eye tracking. Active vs. sham treatment will be randomly assigned in a 1:1 fashion in groups using computer generated lists. Subjects and evaluators will be blind to treatment. All subjects will repeat the baseline assessments after 1st session, 5th session,10th session and within 3 days after 10th session.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Shanghai Mental Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
(1) 65≤age≤75 years old; (2) years of education ≥1 year; (3) normal daily life ability; (4) total score of The Chinese version of Mini-Mental State Examination (MMSE) : Non-illiterate group (not graduated from elementary school)> 14 points, elementary school group> 19 points, middle school and above group> 24 points).
Exclusion Criteria:
(1) People with obvious hearing, vision problems or communication difficulties; (2) People with obvious cognitive dysfunction (such as Alzheimer's disease); (3) People with serious medical diseases (such as heart disease, uremia, severe diarrhea) ; (4) In the stage of radiotherapy and chemotherapy; (5) People with serious neurological diseases (such as Parkinson's disease, infectious encephalopathy); (6) Patients with mental diseases (such as schizophrenia, depression, etc.); 7) Patients with substance abuse or alcohol dependence; (8) patients with implantable medical devices such as cardiac pacemakers; (9) patients with scars or inflammation on the ear skin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active tVNS group
The active tVNS group will be stimulated with 10 sessions of active transcutaneous vagal nerve stimulation (tVNS)
|
One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus.
Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.
|
Sham Comparator: Sham tVNS group
The sham tVNS group will be stimulated with 10 sessions of sham transcutaneous vagal nerve stimulation (tVNS)
|
Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes.
Except for the stimulation site, other parameters are the same as active group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cognition
Time Frame: up to 2 weeks(end of the intervention)
|
Identifying cognitive affected domains by using Cambridge Neuropsychological Test Automated Battery (CANTAB) (Memory:PAL、DMS、PRM; Executive Function : RTI、MOT)
|
up to 2 weeks(end of the intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cognition
Time Frame: within 1 day after 1st session and 5th session and 1-week follow-up
|
Identifying cognitive affected domains by using Cambridge Neuropsychological Test
|
within 1 day after 1st session and 5th session and 1-week follow-up
|
PHQ-9
Time Frame: up to 2 weeks(end of the intervention),1-week follow-up
|
Patient Health Questionnaire-9 items,values:0-27, higher score indicates more severe depression symptoms
|
up to 2 weeks(end of the intervention),1-week follow-up
|
GAD-7
Time Frame: up to 2 weeks(end of the intervention),1-week follow-up
|
Generalized Anxiety Disorder-7,values:0-21, Higher score indicates more severe anxiety symptoms
|
up to 2 weeks(end of the intervention),1-week follow-up
|
Relative power for delta, theta, alpha, sensorimotor and lower beta frequency bands.
Time Frame: up to 2 weeks(end of the intervention)
|
The power spectral density was calculated to extract the relative power for each frequency band and estimated as a log-ratio.
|
up to 2 weeks(end of the intervention)
|
Antisaccade latency
Time Frame: up to 2 weeks(end of the intervention)
|
We used an EyeLink Desktop 1000 eye-tracker to collect the information of eye movements.The latency of the saccade was measured from the onset of the saccade to the target onset.
|
up to 2 weeks(end of the intervention)
|
Side-effects of tVNS
Time Frame: At each stimulation session, up to 2 weeks.
|
At each stimulation session, up to 2 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chunbo Li, PHD, Shanghai Mental Health Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-64
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
-
Beijing HospitalBGI-ShenzhenCompletedAging | Healthy Aging
-
Northumbria UniversityUniversity of East AngliaSuspendedSleep | Aging | Healthy AgingUnited Kingdom
Clinical Trials on Active tVNS
-
Fondazione Toscana Gabriele MonasterioAzienda Ospedaliera Città della Salute e della Scienza di TorinoNot yet recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Midrange Ejection FractionItaly
-
Istituti Clinici Scientifici Maugeri SpARecruitingHeart Failure With Preserved Ejection Fraction | Heart Failure With Midrange Ejection FractionItaly
-
University of California, Los AngelesUniversity of OklahomaRecruitingAtrial FibrillationUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedHand Osteoarthritis | Erosive Osteo-ArthritisFrance
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingMajor Depressive DisorderUnited States
-
Queen Mary University of LondonKing's College LondonWithdrawn
-
Massachusetts General HospitalNational Institutes of Health (NIH); National Center for Complementary and...Recruiting
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of Excellence (ACE); Feinstein Institute for Medical Research...RecruitingJuvenile Idiopathic Arthritis (JIA)United States
-
Foundation for Prader-Willi ResearchRTI InternationalRecruitingPrader-Willi SyndromeUnited States
-
University of FloridaCompletedStress, Psychological | Sleep | Vagus Nerve Stimulation | Mindfulness | Transcutaneous Electric Nerve StimulationUnited States